Mechanisms of normal and tumor-derived angiogenesis.

By M. Papetti, I. Herman. American Journal of Physiology - Cell Physiology, 2002

846 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Improving Conventional Enhanced Permeability and Retention (EPR) Effects; What Is the Appropriate Target? (2013, background): “(17-19) Unlike the microvasculature of normal tissue, which has an organized and regular branching order, tumor microvasculature shows disorganization and lack of the conventional hierarchy of blood vessels.”
Cerebral Microvessel Responses to Focal Ischemia (2003, background): “The formation of new microvessels from existing vessels (angiogenesis) is a hallmark tissue response to injury (Dvorak et al., 1995; Carmeliet, 2000; Papetti and Herman, 2002; Hynes, 2002).”
Therapeutic targeting of the tumor microenvironment. (2005, neutral): “A plethora of antiangiogenic agents inhibiting either angiogenic growth fac tors or their receptors have been developed (see Table 1 for examples) and tested in preclinical experiments (Papetti and Herman, 2002).”
Diabetes and Wound Angiogenesis (2017, background): “While basal levels of pro-angiogenic factors and the expression of their corresponding receptors are maintained during the healthy state of homeostasis, the diseased state exhibits upregulated expression of pro-angiogenic factors such as VEGF, fibroblast growth factor (FGF), and others to promote un”